Navigation Links
Conatus Pharmaceuticals Terminates Phase 2 Clinical Trial of CTS-1027
Date:10/25/2011

SAN DIEGO, Oct. 25, 2011 /PRNewswire/ -- Conatus Pharmaceuticals Inc. announced today the termination of its Phase 2 clinical trial of CTS-1027 in HCV patients.  This decision follows reports of laboratory abnormalities and adverse events in a subset of clinical trial participants.

The top priority of Conatus is patient safety, and the Company has made the decision to halt this study.  Conatus is conducting a thorough review of the available data to assess any future development of the compound.

Conatus Pharmaceuticals Inc. is a privately-held biopharmaceutical company engaged in the development of innovative human therapeutics in the areas of fibrotic disease and oncology. Conatus' lead drug candidate, emricasan (IDN-6556) is in development as a potential therapy for a variety of fibrotic diseases. Fibrotic diseases affect millions of people worldwide and can be caused by many different types of injuries. Conatus was founded by the executive management team of Idun Pharmaceuticals in July 2005 following the sale of Idun to Pfizer.  Conatus acquired the Idun subsidiary from Pfizer in 2010.  For additional information, please visit www.conatuspharma.com.


'/>"/>
SOURCE Conatus Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Oramed Pharmaceuticals Chosen to Present at the Diabetes Technology Meeting (October 27-29, 2011; San Francisco, CA)
2. Pacira Pharmaceuticals, Inc. Announces Timing for Third Quarter 2011 Financial Results Webcast and Conference Call
3. Syndax Pharmaceuticals to Present at Upcoming Fall Conferences
4. Avanir Pharmaceuticals to Present Data at MS-Focused ECTRIMS Annual Meeting
5. Regeneron Pharmaceuticals Announces Proposed Offering of Convertible Senior Notes due 2016
6. Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data to Be Presented at Upcoming Medical Meetings
7. Inspiration Biopharmaceuticals Announces Acceptance of European Marketing Authorization Application for IB1001 for the Treatment of Hemophilia B
8. Elevation Pharmaceuticals Presents Positive Phase 2a Results in COPD Patients at the European Respiratory Society Annual Congress
9. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in Zerenex™ (Ferric Citrate) Phase 3 Long-Term Study
10. Anadys Pharmaceuticals Updates Its Presentation Date at the Stifel Nicolaus Healthcare Conference
11. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2017)... ... October 06, 2017 , ... ... genomic technologies, launched its ProxiMeta™ Hi-C metagenome deconvolution product, featuring the first ... accompanying cloud-based bioinformatics software to perform Hi-C metagenome deconvolution using their own ...
(Date:10/6/2017)... ... October 06, 2017 , ... The HealthTech Venture ... sector at their fourth annual Conference where founders, investors, innovative practitioners and collaborators ... ELEVATE pitch competition showcasing early stage digital health and med tech companies. , ...
(Date:10/5/2017)... ... 2017 , ... LabRoots , the leading provider of educational and interactive ... back to cancer research with a month-long promotion supporting the advancement of breast cancer ... can use promo code PinkRibbon to get 10 percent off their purchase of every ...
(Date:10/5/2017)... , ... October 05, 2017 , ... ... develop new applications of its Nanobind DNA/RNA extraction technology . Nanobind is ... silica on the surface and that can be used for a wide variety ...
Breaking Biology Technology:
(Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... to expand at a CAGR of 25.76% during the ... is the primary factor for the growth of the ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem ... technology, application, and geography. The stem cell market of ...
(Date:4/3/2017)... , April 3, 2017  Data captured ... engineering platform, detected a statistically significant association ... prior to treatment and objective response of ... potential to predict whether cancer patients will ... treatment, as well as to improve both pre-infusion ...
(Date:3/30/2017)... -- The research team of The Hong Kong Polytechnic ... by adopting ground breaking 3D fingerprint minutiae recovery and matching technology, ... accuracy for use in identification, crime investigation, immigration control, security of ... ... A research team led by Dr ...
Breaking Biology News(10 mins):